

Thoracic Monophasic Synovialosarcoma in a 17 Year Old Girl: A Case Report

ZONGO Esdras^{1,3}, SIDKI Sanaa^{1,3}, KARAM Rajaa^{2,3}, ENNAKRI Abdellatif^{1,4}, CHEKRINE Tarek^{1,3}, BOURHAFOUR Mouna^{1,3}, BOUCHBIKA Zineb^{1,3}, BENCHAKROUN Nadia^{1,3}, JOUHADI Hassan^{1,3}, SAHRAOUI Souha^{1,3}, MARNISSI Farida^{2,3}, TAWFIK Nezha^{1,3}, BENIDER Abdellatif^{1,3}

¹Department of Radiotherapy and Oncology, CHU Ibn Rochd Casablanca, Morocco

²Anatomy Pathology Department, CHU Ibn Rochd Casablanca, Morocco

³Faculty of Medicine and Pharmacy, Hassan II University Casablanca, Morocco

⁴Faculty of Sciences, Mohamed V University Rabat, Morocco

DOI: [10.36347/sjmcr.2021.v09i08.016](https://doi.org/10.36347/sjmcr.2021.v09i08.016)

| Received: 12.07.2021 | Accepted: 16.08.2021 | Published: 29.08.2021

*Corresponding author: Zongo Esdras

Abstract

Case Report

Synovialosarcomas are rare, malignant mesenchymal tumors common in adolescents and young adults. They preferentially affect the lower limbs. Much more rarely, at the level of the chest wall. Contrary to its name, synovialosarcoma does not develop from synovial tissue. We report the case of a 17-year-old adolescent girl, followed for monophasic synovialosarcoma of the chest wall, the diagnosis of which was confirmed by immunohistochemistry. Treatment consisted of neoadjuvant poly chemotherapy followed by concomitant radio chemotherapy and closing surgery. This observation confirms the value of multimodal management in the treatment of this type of pathology.

Keywords: Synovialosarcoma, Thoracic, Monophasic, Immunohistochemistry, Surgery, Radio chemotherapy.

Copyright © 2021 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

INTRODUCTION

Soft tissue sarcomas are rare, malignant mesenchymal tumors of high grade malignancy, the 4th most common soft tissue sarcoma representing 5% to 10% of cases [1]. Synovialosarcomas usually develop in adolescent and young patients near the extremities of the joints [2] and are predominantly in males [3]. They present three histological aspects: the biphasic form; the fibrous monophasic form and the poorly differentiated form (PDSS) [4]. This can be confirmed by immunohistochemistry but a cytogenetic signature is required. Detection of a specific SYT-SSX fusion transcript, a product of the t(X;18) translocation (p11.2;q11.2), confirms the diagnosis [5]. The treatment is multimodal with surgery, chemotherapy and radiotherapy.

CLINICAL OBSERVATION

We report the clinical observation of a 17-year-old female patient, with no personal or family history, who consulted for the appearance of a

supraclavicular mass that had been present for about 4 months and had progressively increased in volume without any other associated signs. The clinical examination noted a good general condition and a bulging ulcerated mass above the right clavicle with pus production. The radiological workup made of CT scan (Figure 1) and magnetic resonance imaging showed a process in the right supraclavicular area. A biopsy was performed, histological and immunohistochemical examination showed a monophasic synovialosarcoma in its cystic variant at least grade II (Figure 2 and Figure 3). Polychemotherapy with adriamycin and ifosfamide resulted in a reduction in tumor mass after 6 courses. A decision of the multidisciplinary consultation meeting preferred positron emission tomography to map the lesions and then concomitant radio-chemotherapy at a dose of 50 Gy to surgery considering the sub-clavicular vasculonervous relationships. An ablation of the tumor residue was performed after radiotherapy. Local recurrence and pleural metastasis was noted after an eighteen-month period, which was treated with palliative chemotherapy.




Figure 1: Transverse scanographic section showing the mass in the right upper clavicular region




Figure 2: Histological appearance of monophasic synovial sarcoma: Monomorphic tumor cells with poorly defined cytoplasm, oval nuclei, homogeneous fine cytoplasm and richly vascularized. (Hx400 and Hx100)




Figure 3: Histological appearance of monophasic synovial sarcoma: Positive expression of EMA, Cytokeratin 7, Cytokeratin AE1 / AE3 and hemangiopericytic vascularization

DISCUSSION

Synovial sarcoma, the fourth high-grade histological variety of sarcoma, is a rare tumor [6]. It develops from a pluripotent mesenchymal cell with synovial differentiation [7] and is mostly found in adolescents and young adults with a male predominance and a sex ratio of 2.1 [8]. Our patient is a female, 17 years old. The localizations are the periarticular regions (80% of cases) and the soft tissues (5-10% of cases) [7]. Thoracic involvement occurs in 8% of cases [9].

It presents as a soft mass, progressively increasing in size over several months or years [10], with curvature of the wall, when it develops outwardly. It may be asymptomatic [9] or responsible for chest pain, progressively increasing, as in our observation for several months [10, 11]. Radiologically, CT scans allow a better appreciation of the presence of micro-calcifications, to specify the endo- and exo-thoracic extension of the tumor [7]. On magnetic resonance imaging, approximately 90% of synovial sarcomas are well limited with a capsule-like appearance; the presence of lobulations or septa is common [12]. In 80% of cases, tumors are T2 heterogeneous with fluid, solid, or fibrous tone signals [7]. On pathological examination, the tumor is oval or rounded in shape, sometimes multi-nodular, often well delimited and encapsulated, pale, whitish or grayish in color, and with a soft consistency. Three subtypes of synovial sarcoma can be distinguished: the monophasic form (31%), the biphasic form (33%), and the undifferentiated form (36%) [7]. On immunohistochemistry, synovial sarcomas express Epithelial Membrane Antigen (EMA) and cytokeratins in 90% of cases, CD99 in 60% of cases and S100 protein in 30% of cases [13]. In our patient, the immunohistochemical study showed the negativity of S100 protein, cytokeratin, vimentin and EMA positivity. By identifying by Fish or RT-PCR the presence of a specific fusion transcript SYT-SSX, resulting from the translocation t(X;18) (p11.2; q11.2), the cytogenetic analysis of the tumor cells confirmed the diagnosis of synovial sarcoma [5].

Several prognostic factors have been suggested which are mainly: age, location, tumor size, high mitotic index and Ki-67 greater than 10% [14, 15]. Among these, in our patient, we find size, age and thoracic location. Treatment is multimodal combining surgery and radio-chemotherapy [7]. The combination of chemotherapy with radiotherapy is not standard, it potentiates the response of radiotherapy to allow resection of the mass [7]. The recurrence rate of locoregional or metastatic disease at two years is 50%. These recurrences are more frequent during the first two years and affect more regional lymph nodes, lung, bone and liver (16). The prognosis is generally poor due to local and metastatic recurrence [17].

CONCLUSION

Synovial sarcoma of the chest wall, a rare malignancy; its treatment is multimodal based on extensive, complete surgery and neoadjuvant or adjuvant chemotherapy and external radiotherapy. The prognosis is poor due to frequent local and metastatic recurrences. Our observation highlights the interest of multidisciplinary collaboration in the treatment of this tumor.

Conflict of Interest: The authors declared no conflict of interest.

ACKNOWLEDGMENTS: Our sincere thanks to Professor TAWFIK Nezha for his supervision in the relaying of this work and to KOFFO wife LALLE Grace Benjamine for her linguistic contribution.

REFERENCE

- Krieg, A. H., Hefti, F., Speth, B. M., Jundt, G., Guillou, L., Exner, U. G., ... & Siebenrock, K. A. (2011). Synovial sarcomas usually metastasize after > 5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors. *Annals of oncology*, 22(2), 458-467.
- Trolliet, S., Lindner, V., Krzisch, S., Schneider, M., & Jung, J. L. (2014). Synovial sarcome rénal primitif. *Progrès en urologie*, 24(3), 156-160.
- Zeren, H., Moran, C. A., Suster, S., Fishback, N. F., & Koss, M. N. (1995). Primary pulmonary sarcomas with features of monophasic synovial sarcoma: a clinicopathological, immunohistochemical, and ultrastructural study of 25 cases. *Human pathology*, 26(5), 474-480.
- van de Rijn, M., Barr, F. G., Xiong, Q. B., Hedges, M., Shipley, J., & Fisher, C. (1999). Poorly differentiated synovial sarcoma: an analysis of clinical, pathologic, and molecular genetic features. *The American journal of surgical pathology*, 23(1), 106-112.
- Turc-Carel, C., Dal Cin, P., Limon, J., Li, F., & Sandberg, A. A. (1986). Translocation X; 18 in synovial sarcoma. *Cancer Genetics and Cytogenetics*, 23(1), 93.
- Kouhen, F., Afif, M., Benhmidou, N., & Rais, F. (2015). Le synovial sarcome de la sphère otorhino-laryngée: une localisation rare: à propos de deux cas. *The Pan African Medical Journal*, 20.
- Qassimi, L., El Khattabi, W., Lyousfi, H., Aichane, A., & Afif, H. (2015). A rare tumor of the chest wall: the synovial sarcoma. *Revue de pneumologie clinique*, 71(4), 251-252.
- Raveendran, S., Kota, A. A., Stephen, E., Pallapati, S. C., & Thomas, B. P. (2018). Synovial sarcoma of the brachial plexus—a rare tumor in a rare area: a case report. *Journal of medical case reports*, 12(1), 1-4.

9. Bui-Mansfield, L. T., Kaplan, K. J., & Boardman, J. (2002). Radiologic-pathologic conference of Keller Army Community Hospital at West Point, the United States Military Academy: synovial sarcoma of the chest wall. *American Journal of Roentgenology*, 179(4), 880-880.
10. Riquet, M., Carnot, F., Lepimpec-Barthes, F., Debrosse, D., & Debesse, B. (1994). A rare tumor of the thoracic wall: synovial sarcoma. *Revue des maladies respiratoires*, 11(4), 424-427.
11. Duran-Mendicuti, A., Costello, P., & Vargas, S. O. (2003). Primary synovial sarcoma of the chest: radiographic and clinicopathologic correlation. *Journal of thoracic imaging*, 18(2), 87-93.
12. Remy, O., Messouna, M., Akimana, G., Kamdem, M., & Errihani, H. (2020). Le synoviosarcome du poumon: à propos d'un cas et revue de la littérature. *The Pan African Medical Journal*, 36.
13. Afif, H., El Khattabi, W., Maarif, H., Nassaf, M., & Trombati, N. (2006). Une masse de la paroi thoracique. *La Revue de médecine interne (Paris)*, 27(4), 342-343.
14. Amble, F. R., Olsen, K. D., Nascimento, A. G., & Foote, R. L. (1992). Head and neck synovial cell sarcoma. *Otolaryngology—Head and Neck Surgery*, 107(5), 631-637.
15. Skytting, B. T., Bauer, H. C., Perfekt, R., Nilsson, G., & Larsson, O. (1999). Ki-67 is strongly prognostic in synovial sarcoma: analysis based on 86 patients from the Scandinavian Sarcoma group register. *British journal of cancer*, 80(11), 1809-1814.
16. Kallel, S., Mnejja, M., Ghorbel, L., Kallel, R., Charfeddine, I., Hammami, B., & Ghorbel, A. (2013). Synoviosarcome cervical: a propos d'un cas. *Journal Tunisien d'ORL et de Chirurgie Cervico-Faciale*, 30, 67-69.
17. Blankenburg, S., Petersen, I., Katenkamp, D., & Chilla, R. (2011). An unusual case of a synovial sarcoma of the parotid gland in an elderly patient. *Auris Nasus Larynx*, 38(4), 523-527.